Author

Dai Liu

Institution: Intellia Therapeutics (United States)

Observed institution: Intellia Therapeutics (United States)

ORCID: 0000-0002-7479-2237

Observed ORCID: 0000-0002-7479-2237

OpenAlex ID: A5075896421

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function

2022 · Eliana Ruggiero, Erica Carnevale, et al. · Science Translational Medicine · 58

A differentiated and durable allogeneic strategy applicable to cell therapies

2025 · Utsav Jetley, Ishina Balwani, et al. · Cytotherapy · 6

Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activity

2026 · Ivy Dutta, Justin Oh, et al. · bioRxiv (Cold Spring Harbor Laboratory)

388 Engineering co-stimulation into TCR-T cells via a CD8–41BB fusion receptor enhances efficacy and durability in preclinical models of heme and solid tumor malignancies

2024 · Aaron Prodeus, Ivy Dutta, et al. · Journal for ImmunoTherapy of Cancer

Works count: 4

Citation count: 64

H-index: 2

I10-index: 1